| ADME | absorption, distribution, metabolism and excretion |
| AML | acute myeloid leukemia |
| ATP | adenosine triphosphate |
| AUC | Area under curve |
| BBB | blood brain barrier |
| BTZ | Bortezomib |
| CAM | chick chorioallantois membranes |
| CD2 | catalytic domain 2 |
| Cmax | maximum serum concentration of drug in a specified compartment of the body |
| conc. | concentrated |
| CRBN | E3 ubiquitin cereblon ligase |
| DFMO | difluoromethyl-1,3,4-oxadiazole |
| FA | formic acid |
| GI50 | concentration that causes 50% growth inhibition of cells |
| HB | hydrogen bonding |
| HD | Huntington disease |
| HDAC | Histone deacetylase |
| HDACi | Histone deacetylase inhibitor |
| HTS | hight throughput screening |
| IC50 | concentration that causes 50% enzyme inhibition |
| nM | nanomolar |
| PBMCs | peripheral blood mononuclear cells |
| PHA | phytohemagglutinin |
| PROTAC | proteolysis-targeting chimeras |
| SIRT | Sirtuins |
| smHDAC | HDAC from Schistosoma mansoni |
| t1/2 | half-life period |
| TFMO | trifluoro-1,2,4-oxadiazole |
| Tmax | time of peak plasma concentration |
| VHL | Von-Huppel–Lindau ligase |
| ZBG | Zinc binding group |
| zHDAC6 | zebrafish HDAC6 |